The U.S. Food and Drug Administration has granted Orphan Drug Designation to EPX-100 and EPX-200 for the treatment of patients with Dravet syndrome. Dravet Syndrome qualifies as a rare pediatric disease under Section 529 of Food, Drug, and Cosmetic Act. The rare, catastrophic, lifelong form of epilepsy begins in the first year of life with frequent or prolonged seizures. Intellectual disability, behavioral abnormalities, gait and motor dysfunction, and increased mortality are commonly observed as the disease progresses. Patients with Dravet Syndrome also suffer with life-threatening seizures that cannot be adequately controlled by available medications, and face a 15-20 percent mortality rate due to SUDEP (Sudden Unexplained Death in Epilepsy), seizure-related accidents such as drowning, o...
Promising results from a large-scale, controlled, Phase 3 clinical study of epilepsy patients being treated with cannabidiol will be presented next week at the American Academy of Neurology’s Annual Meeting in Boston on April 25. GW Pharmaceuticals’ liquid oral formulation of cannabidiol (CBD), called Epidiolex, is one of 500 compounds found in cannabis. Unlike the well-known compound, tetrahydrocannabinol (THC), CBD does not produce a “high” as the psychoactive component is absent. Results from the randomized, double-blind, placebo-controlled study found that almost 40 percent of people with Lennox-Gastaut syndrome (LGS) had at least a 50 percent reduction in drop seizures, compared to 15 percent taking a placebo. LGS is a severe form of epilepsy that often results in impaired intellectua...
Consider two children who have childhood absence epilepsy (CAE), the most common form of pediatric epilepsy. They both take the same drug—one child sees an improvement in their seizures, but the other does not. A new study in the Annals of Neurology identified the genes that may underlie this difference in treatment outcomes, suggesting there may be potential for using a precision medicine approach to help predict which drugs will be most effective to help children with CAE. The study was funded by the National Institute of Neurological Disorders and Stroke (NINDS) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), both part of the National Institutes of Health. “A better understanding of genetic factors underlying a disease and the way t...
The first refractory epilepsy patients have been implanted with Prometra II programmable infusion pumps for a clinical trial of the dose-delivery devices, according to the product’s developers, Flowonix Medical and Cerebral Therapeutics. Dan Abrams, Cerebral Therapeutics’ CEO, said the multi-center ADDRESS trial is the first study of programmable, implantable pumps delivering medication directly to the brain — what is called intracerebroventricular delivery.
Researchers at Carnegie Mellon University have developed a new device that detects ongoing epileptic seizures and suppresses them as they start, according to a recent study. This approach may evolve into a non-invasive method to treat epileptic seizures.
Researchers suggest that Marmite may benefit brain function. Marmite is far from one of the most popular foods in the United States. In fact, many Americans are unlikely to have heard of it. A new study, however, suggests that when it comes to boosting brain function, Marmite triumphs over peanut butter.
When Yuan Yingjin turned 54 on March 10, he had two unusual presents: some yeast chromosomes and acclaim in China’s national news. That day, research into assembling four synthetic yeast chromosomes, completed by his Tianjin University research team and scientists at Tsinghua University and BGI-Shenzhen, was published in the famous journal Science. The achievement made China the second country after the US capable of designing and building eukaryotic genomes.
The teenager languished for three days in a Halifax hospital room, hooked up to an electroencephalogram (EEG) and watched by camera in a routine assessment of the young person’s epilepsy. The results were unremarkable, the EEG readings mostly normal. But then doctors noticed two sudden “bursts” of activity on the brain monitor typically associated with epileptic seizures. What the video of the patient revealed was more surprising.
More than 50 million people of all ages suffer from epilepsy, otherwise known as seizure disorder, the fourth most common neurological disease in the world. Patients diagnosed with epilepsy often experience recurrent seizures triggered by the firing of a large collection of neurons in the brain. This ultimately generates a high-energy wave that spreads across the surface of the brain, resulting in numerous physical effects such as erratic body shaking, unconsciousness, exhaustion, and pain.
There is a growing interest over the possible relationship between depression and epilepsy. A study recently published showed that there is an increased risk of developing epilepsy among persons diagnosed with depression, and vice versa. Epilepsy is a syndrome characterized by recurrent, unprovoked seizures due to an imbalance of chemicals in the nervous system. This chemical imbalance is also one of the underlying mechanisms of depression. This similarity in pathophysiology has sparked an interest among the medical community to determine the possible relationship between the two diseases.
New King’s College London research reveals how genetic defects can lead to epilepsy in children. In their new study, published in Scientific Reports and funded by Eli Lilly and Co., the researchers set out to understand how genetic defects affect electrical transmission in the brain. Understanding exactly how nerve cells are misfiring and creating seizures in children with epilepsy will allow researchers to design better, more personalised treatments for epilepsy.
A novel statistical approach to analyzing patients with epilepsy has revealed details about their brains’ internal networks. The findings may lead to better understanding and treatment of the disease, according to Rice University researchers.